Heparin induced thrombocytopenia: Pathogenetic, clinical, diagnostic and therapeutic aspects

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 7, Issue 3, 2007, Pages 153-162

  Castelli, R ^a   Cassinerio, E ^b   Cappellini, M D ^b   Porro, F ^a   Graziadei, G ^a   Fabris, F ^c  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

Heparin; Heparin induced thrombocytopenia; LMWH; PF4 heparin immunocomplex; Thrombocytopenia

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; CYTOKINE; DANAPAROID; DICOUMAROL DERIVATIVE; ENOXAPARIN; FC RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARAN SULFATE; HEPARIN; HEPARINOID; HIRUDIN; HIRULOG; ILOPROST; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBOCYTE FACTOR 4; TIROFIBAN; WARFARIN;

ANAPHYLAXIS; BLEEDING; CLINICAL FEATURE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG WITHDRAWAL; ENDOTHELIUM CELL; ENDOTHELIUM LESION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIOLOGICAL DATA; GANGRENE; HEART SURGERY; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HUMAN; IMMUNOGENICITY; IN VITRO STUDY; INCIDENCE; LABORATORY TEST; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; ORTHOPEDIC SURGERY; PATHOGENESIS; PATHOPHYSIOLOGY; RECOMMENDED DRUG DOSE; REVIEW; SKIN NECROSIS; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS;

ANIMALS; ANTICOAGULANTS; CHONDROITIN SULFATES; DERMATAN SULFATE; HEPARIN; HEPARITIN SULFATE; HIRUDINS; HUMANS; PEPTIDE FRAGMENTS; PIPECOLIC ACIDS; POSTOPERATIVE COMPLICATIONS; RECOMBINANT PROTEINS; THROMBOCYTOPENIA;

EID: 34848831729     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152907781745251     Document Type: Review

References (112)

1. Davey, M.G., Lander, H. Effect of injected heparin on platelet levels in man. J. Clin. Pathol., 1968, 2, 55-59.
2. Fabris, F., Ahmad, S., Cella, G., Jeske, W.P., Walenga, J.M., Farced J. Pathophysiology of heparin-induced thrombocytopenia, clinical and diagnostic implications- A review. Arch. Pathol. Lab. Med., 2000, 124, 1657-1666.
3. Zucker, M.B. Heparin and platelet function. Fed Proc., 1977, 36, 47-9.
4. Fondu, P. Heparin associated thrombocytopenia: an update. Acta Clin. Belgica, 1995, 50, 343-57.
5. Chong, B.H. Heparin induced thrombocytopenia. Br. J. Haematol., 1995, 89, 431-9.
6. Fabris, F., Luzzato, G., Stefani, P.M., Girolami, B., Cella, G., Girolami, A. Heparin induced thrombocytopenia. Haematologica, 2000, 85, 72-80.
7. Deitcher, S.R., Barman, T.L. Heparin-induced thrombocytopenia: natural history, diagnosis and management. Vascular Medicine, 2001, 6, 113-119.
8. Visentin, G.P., Ford, S.E., Scott, J. P. Antibodies from patients with heparin -induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cell. J. Clin. Invest., 1994, 93, 81-88.
9. Amiral, J., Wolf, M., Fisher, A., Boyer-Neumann, C., Vissac, A., Meyer, D. Pathogenicity of IgA, and or IgM antibodies to heparin-PF4 complexes in patients with heparin induced thrombocytopenia. Br. J. Haematol., 1996, 92, 954-59.
10. Greinacher, A., Potzach, B., Amiral, J., Dummel, V., Eichner, A., Mueller-Eckhardt, C. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multi-molecular PF4-heparin complex as the major antigen. Thromb. Haemost., 1994, 71, 247-51.
11. Rhodes, G.R., Dixon, R.H., Silver, D. Heparin induced thrombocytopenia with thrombotic and hemorrhagic manifestations. Surg. Gynecol, Obstet., 1973, 3, 409-16.
12. Greinacher, A., Michels, I., Mueller-Eckhardt, C. Heparin - associated thrombocytopenia: the antibody is not heparin specific. Thromb Haemost., 1992, 67, 545-9.
13. Greinacher, A., Michels, I., Liebenhoff, P., Presek, P., Mueller-Eckhardt, C. Heparin-associated thrombocytopenia: immune complexes are attached to platelet membrane by negative charge highly sulphated oligosaccharides. Br. J. Haemtol., 1993, 84, 711-6.
14. Kelton, J.G., Smith, J.W., Warkentin, T.E., Hayward, C.P., Denomme, G.A., Horsewood, P. Immunoglobulin G from patients with heparin induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood, 1994, 83, 3232-9.
15. Gruel, V., Boizard-Boval, B., Wautier, J.L. Further evidence that alpha-granule component such as platelet factor 4 are involved in platelet IgG heparin interactions during associated thrombocytopenia. Thromb. Haemostasis, 1993, 70, 374-5.
16. Greinacher, A., Michels, I., Muller- Eckhardt, C. Heparin associated thrombocytopenia: the antibody is not heparin specific. Thromb. Haemostasis, 1992, 67, 545-49.
17. Savi, P., Pfligger, A.M., Herault, J.P. Comparative effects of two syntetic oligosaccarides on platelet activaction induced by plasma from HIT patients. J. Thromb. Haemostasis, 2003, 9, 2008-2013.
18. Rauova, L., Poncz, M., Mc Kenzie, S.E., Reilly, M.P., Arepally, G., Weisel, J.W., Nagaswami, C., Cines D.B., Sachais B.S. Ultra large complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood, 2005, 105, 131-138.
19. Butena, S., Cowthern, K.M., van't Veer, C., Di Lorenzo, M.E., Lock, J.B. Antiplatelet agents in tissue factor induced blood coagulation. Blood, 2001, 97, 2314-22.
20. Kwan, J.C., Sakurai, S. Endothelial cell hyperplasia contributes to thrombosis in heparin induced thrombocytopenia. Sem. Thromb. Hemost, 1999, 25, (8 suppl. 1), 23-27.
21. Khairy, M., Lasne, D., Amelot, A., Crespin, M., Rendu, F., Aiach, M., Bachelot-Loza, C. Polymorphonuclear leukocyte and monocyte activation induced by plasma from patients with heparin-induced thrombocytopenia in whole blood. Thromb. Haemost., 2004, 92(6), 1411-1419.
22. Warkentin, T.E. Heparin induced thrombocytopenia a clinical pathological syndrome. Thromb. Haemost., 1999, 82, 439-447.
23. Chong, B.H. Heparin induced thrombocytopenia. Austr. N. Z. J. Med., 1992, 6, 145-52.
24. Schmitt, B.P., Adelmann, B. Heparin associated thrombocytopenia: a critical review and pooled analysis. Am. J. Med. Sci., 1993, 305, 208-15.
25. Kappers-Klunne, M.C., Boon, D.M., Hop, W.C., Michiels, J.J., Stibbe, J., van der Zwann, C., Koudstaal, P.J., van Vliet, H.H. Heparin induced thrombocytopenia and thrombosis: a prospective analysis of the incidence in patients with heart and cerebrovascular disease. Br. J. Haematol., 1997, 96, 442-44.
26. Girolami, B., Prandoni, P., Stefani, P.M., Tanduo, C., Sabbion, P., Eicchler, P., Ramon, R., Baggio, G., Fabris, F., Girolami, A. The incidence of heparin induced thrombocytopenia in hospitalised medical patients treated with subcutaneous unfractioned heparin: a prospective cohort study. Blood, 2003, 10, 2955-59.
27. Warkentin, T.E., Levine, M.N., Hirsh, J., Horsewood, P., Roberts, R.S., Gent, M., Kelton, J.G. Heparin induced thrombocytopenia in patients with treated with low molecular weight or unfractionated heparin. N. Engl. J. Med., 1995, 332, 1330-1335.
28. Locke, C.F.S., Dooley, J., Gerber, J. Rates of clinically apparent heparin-induced thrombocytopenia for unfractionated heparin vs. low molecular weight heparin in non-surgical patients are low and similar. Thromb. J., 2005, 3(1), 4.
29. Prandoni, P, Siragusa, S, Girolami, B, Fabris, F., Belzoni Investigator Group. The incidence of heparin induced thrombocytopenia in medical patients treated with low molecular weight heparin: a prospective cohort study. Blood, 2005, 106, 3049-54.
30. Boskow, L., Warkentin, T.E., Hayward, C.M.P., Andrew, M., Kelton, J.G. Heparin induced thrombocytopenia and thrombosis: clinical and laboratories studies. Br. J. Haematol., 1993, 84, 322-328.
31. Nand, S., Wong, W., Yueben, B., Yetter, A., Schmulbach, E., Gross Fischer, S. Heparin induced thrombocytopenia with thrombosis: incidence, analysis of risk factors and clinical out come in 108 consecutive patients treated in a single institution. Am. J. Hematol., 1997, 56, 12-16.
32. Warkentin, T.E. Heparin induced skin lesions. Br. J. Haematol., 1996, 92, 494-97.
33. Warkentin, T.E. Clinical picture of heparin induced thrombocytopenia. In Heparin Induced thrombocytopenia; Warkentin, T.E., Greinacher, A. Editors Marcel, Dekker, 2001.
34. Fabris, F., Luzzato, B., Soini, B., Ramon, R., Scandellari, M., Randi, L., Girolami, A. Risk factors for thrombosis in patients with immune mediated heparin induced thrombocytopenia. J. Intern. Med., 2002, 252, 149-154.
35. Singer, R.L., Mannion, J.D., Bauer, T.L., Armenti, F.R., Edie, R.N. Complications from heparin induced thrombocytopenia in patients undergoing cardiopulmonary by-pass. Chest, 1993, 104, 1436-40.
36. Canova, C.R., Cantieni, R., Zellweger, U., Reinhart, W.H. Fatal central pulmonary embolism under heparin therapy: white-clot syndrome. Schweiz. Med. Wochenschr., 1997, 127(18), 762-765.
37. Nasuno, A., Matsubara, T., Hori, T., Higuchi, K., Tsuchida, K., Mezaki, T., Tanaka, T., Moro, H., Hayashi, J., Tanaka, K., Fuse, I., Aizawa, Y. Acute pulmonary thromboembolism induced by prophylactic heparin use and a heparin-coated catheter: a case of heparin-induced thrombocytopenia and thrombosis syndrome. Circul. J., 2003, 67, 96-98.
38. Stockli, T.C., Walther, A., Gorres, G., Ritz, R., Marbet, G.A. Heparin-induced thrombopenia and thrombosis. Schweiz. Med. Wochenschr., 1996, 126(12), 483-488.
39. De Piccoli, B., Martino, A., Zuin, G., Raviele, A. Thrombocytopenia associated with massive cardiac thrombosis during treatment with non fractionated heparin: description of a clinical-case. Ital. Heart. J. Suppl., 2002, 3(8), 869-873.
40. Warkentin, T.E. Venous thromboembolism in heparin-induced thrombocytopenia. Curr Opin. Pulm. Med., 2000, 6(4), 343-351.
41. Gupta, B.K., Savage, M.P., Brest, A.N. Acute myocardial infarction during coronary angioplasty associated with heparin-induced thromocytopenia. Cathet. Cardiovasc. Diagn., 1995, 35(1), 42-46.
42. Laubenthal, F.C., Grosch, B., Szurawitzki, G., Sabin, G. V. Heparin-induced thrombocytopenia type II with early aortocoronary by pass occlusion and stent thrombosis after PTCA of the RCA-treatment with lepirudin (Refludan) and abciximab (Reo pro) during recanalization of the RCA. Z. Kardiol., 1999, 88(2),141-146.
43. Laubenthal, F.C., Grosch, B., Szurawitzki, G., Sabin, G.V. Heparin-induced thrombocytopenia type II with early aortocoronary by-pass occlusion and stent thrombosis after PTCA of the RCA-treatment with lepirudin (Refludan) and abciximab (Reo pro) during recanalization of the RCA. Z. Kardiol., 1999, 88(2), 141-146.
44. Gallagher, M.J., Ajluni, S.C., Almany, S.L. Coronary artery stent thrombois associated with heparin-induced thrombocytopenia: case report and review of the literature. J. Interv. Cardiol., 2005, 18(2), 131-137.
45. LaMonte, M.P., Brown, P.M., Hursting, M.J. Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy. Crit. Care. Med., 2004, 32(4), 976-980.
46. Hayashi, T., Suyama, Y., Kaneko, M., Okamura, J., Nakao, Y., Nonaka, Y., Nomura, T. Heparin-induced thrombocytopenia and thrombosis in a patient with polycytemia vera. Intern. Med., 2004, 43(7), 587-589.
47. Wester, J.P., Haas, F.J., Biesma, D.H., Leusink, J.A., Veth, J. Thrombosis and hemorrhage in heparin-induced thrombocytopenia in seriously ill patients. Intensive Care Med., 2004, 30(10), 1927-1934.
48. Warkentin, T.E., Greinacher, A. Heparin - induced thrombocytopenia recognition, treatment and prevention: the Seventh ACCP Conference on Antithrombotic, and Thrombolytic Therapy. Chest, 2004, 126(3 suppl.), 311S-337S.
49. Warkentin, T.E., Greinacher, A. Heparin - induced thrombocytopenia and cardiac surgery. Ann. Thoracic Surg., 2003, 76, 2121-2131.
50. Abrams, C.S., Cines, D.B. Thrombocytopenia after treatment with platelet glycoprotein IIb/IIIa inhibitors. Curr. Hematol. Rep., 2004, 3, 143-147.
51. Sheridan, D., Carter, C., Kelton, J.G. A diagnostic test for heparin induced thrombocytopenia. Blood, 1986, 67, 27-30.
52. Greinacher, A., Amiral, J., Dummel, V., Vissac, A., Kiefel, V., Mueller-Eckhardt, C. Laboratory diagnosis of heparin associated thrombocytopenia and comparison of platelet aggregation test, heparin induced platelet activation test, and platelet factor 4/heparin enzyme linked immuno-sorbent assay. Transfusion, 1994, 34, 381-85.
53. Chong, B.H., Eisbacher, M. Pathophysiology and laboratory testing of heparin induced thrombocytopenia. Semin. Hematol., 1998, 35(suppl. 4), 3-8.
54. Warkentin, T.E., Hayward, C.P.M., Smith, C.A., Kelly, P.M., Kelton, J.G. Determinants of donor platelet varibility, when testing for heparin induced thrombocytopenia. J. Lab. Clin. Med., 1992, 120, 371-79.
55. Amiral, J. Diagnostic test in heparin induced thrombocytopenia. Platelets, 1997, 8, 68-72.
56. Koch, S., Harenberg, J., Odel, M. Development of an high pressure liquid chromatography method for diagnosis of heparin induced thrombocytopenia. Am. J. Clin. Pathol., 2002, 117, 900-904.
57. Kelton, I.G., Sheridan, D., Santos, A. Heparin induced thrombocytopenia laboratory studies. Blood, 1988, 723, 925-30.
58. Eichler, P., Budde, U., Haase, S., Kroll, H., Loreth, R.M., Mayer, O., Puchman, U., Pötzsch, B., Schabe, A., Albrecht, D., Greinacher, A First Workshop for detection of heparin -induced Antibodies: validation of the Heparin induced Platelet-activation Test (HIPA) in comparison with a PF4/heparin ELISA. Thromb. Haemost., 1999, 81, 625-9.
59. Warkentin, T.E. Laboratory testing of HIT. Journal of thromb. and thrombolysis, 2000, 10, S35-S45.
60. Gobbi, G., Mirandola, P., Tazzari, P.L., Talarico, E., Caimi, L., Martini, G., Papa, S., Conte, R., Manzoli, F.A., Vitale, M. New laboratory test in flow cytometry for combined analisys of serological and cellular parameters in the diagnosis of heparin induced thrombocytopenia. Cytometry B. Clin. Cytom., 2004, 58, 32-38.
61. Vitale, M., Tazzari, P., Ricci, F., Mazza, M.A., Zauli, G., Martini, G., Caimi, L., Manzoli, F.A., Conte, R. Comparison between different laboratory tests for the detection and prevention of heparin induced thrombocytopenia. Cytometry, 2001, 46, 290-295.
62. Greinacher, A., Michels, I., Kiefel, V., Mueller-Eckhardt, C. A rapid and sensitive test for diagnosing heparin induced thrombocytopenia. Thromb. Haemost., 1991, 66, 734-36.
63. Fohlen, W.A., De Maustre, E., Mulat, A., Marchand Arvier, M., Lecompte, T. Does negative heparin platelet factor 4 enzyme-linked immunosorbent assay exclude heparin induced thrombocytopenia? J. Thromb. Haemost., 2003, 1, 1884-5.
64. Warkentin, T.E., Sheppard, J.I., Horsewood, P., Simpson, P.J., Moore, J.C, Kelton, J.G. Impact of patient population on the risk for heparin induced thrombocytopenia. Blood, 2000, 96, 1703-7.
65. Lindhoff-Last, E., Gerdsen, F., Ackermann, H., Bauersachs, R. Determination of heparin ± platelet factor 4 ±Ig G antibodies improves diagnosis of heparin-induced thrombocytopenia. Br. J. Hematol., 2001, 113, 886-890.
66. Warkentin, T.E., Sheppard, J.A., Moore, J.C., Moore, K.M., Sigouin, C.S., Kelton, J.G. Laboratory testing for the antibodies that cause heparin induced thrombocytopenia: How much class do we need. J. Lab. Clin. Med., 2005, 146, 341-46.
67. Wallis, D.E., Quintus, R., Wehrmacher, W., Messmore, H. Safety of warfarin anticoagulation on patients with heparin induced thrombocytopenia. Chest, 1999, 116, 1333-1338.
68. Wallis, D.E., Workman, D.L., Lewis Steen, L., Pifarre, R., Moran, J.F. Failure of early heparin cessation as treatment for heparin induced thrombocytopenia. Am. J. Med., 1999, 106, 629-635.
69. Markwardt, F. The development of hirudin as an antithrombotic drug. Thromb. Res., 1994, 74, 1-23.
70. Greinacher, A. Lepirudin: a bivalent direct thrombin inhibitor for anticoagulation therapy. Expert Rev. Cardiovasc. Ther., 2004, 2(3), 339-357.
71. Magnani, H.N., Gallus, A. Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of ptients treated with Danaparoid (Orgaran) from 1982 to mid-2004. Thromb. Haemost., 2006, 95, 967-981.
72. Farner, B., Eichler, P., Kroll, H., Greinacher, A. A comparison of Danaparoid and Lepirudin in heparin-induced thrombocytopenia. Thromb. and Haemost., 2001, 85, 950-957.
73. Greinacher, A., Volpel, H., Janssens, U., Hach-Wunderle, V., Kemkes-Matthes,-B., Eichler, P., Mueller-Velten, H.G., Potzsch, B. Recombinant Hirudin (lepirudin) provides safe and effective anti-coagulation in patients with heparin induced thrombocytopenia: a prospective study. Circulation, 1999, 99, 73-80.
74. Lubenow, N., Eichler, P., Lietz, T., Greinacher, A. HIT Investigator group. Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT3) and a combined analysis of HAT1, HAT2 and HAT3. J. Thromb. Haemost., 2005, 11, 2428-36.
75. Schiele, F., Vuillemenot, A., Kramarz, P., Kieffer, Y., Anguenot, T., Bernard, Y., Bassand, J. P. Use of recombinant Hirudin as antithrombotic treatment in patients with heparin induced thrombocytopenia. Am. J. Hematol., 1995, 50, 20-25.
76. Eriksson, B.I., Wille-Jorgensen, P., Kalebo, P., Mouret, P., Rosencher, N., Bosch, P., Baur, M., Ekman, S., Bach, D., Lindbratt, S., Close, P. A comparison of recombinant hirudin with low molecular weight heparin to prevent thromboembolic complications after total hip replacement. N. Engl. J. Med., 1997, 337, 1329-35.
77. OASIS Investigators. Comparison of the effects of two doses of recombinant Hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: a pilot study. Circulation, 1997, 96, 769-77.
78. Potzach, B., Madlaner, K., Sellig, C., Riess, C.F., Gremachen, A., Muller Berghaus, G. Monitoring of r-hirudin anticoagulation during cardiopulmonary by-pass: assessment of the whole blood ecarin clothing time. Thromb. Haemost., 1997, 77, 920-25.
79. Hein, O.V., von Heymann, C, Morgera, S., Konertz, W., Ziemer, S., Spies, C. Protracted bleeding after hirudin anticoagulation for cardiac surgery in a patient with HIT II and chronic renal failure. Artif. Organs, 2005, 29(6), 507-509.
80. Warkentin, T.E., Crowther, M.A. Reversing anticoagulants both old and new. Can. J. Anaesth., 2002, 49(6), S11-S25.
81. Fischer, K.G., Lieb, V., Hudek, R., Piazolo, L., Haase, K.K., Borggrefe, M., Huhle, G. Anti-hirudin antibodies alter pharmacocinetics and pharmacodymamics of recombinant Hirudin. Thromb. Haemost., 2003, 6, 973-82.
82. Greinacher, A., Lubenow, M., Eichler, P. Anaphylactic and anaphylactoid reactions associated with Lepirudin in patients with heparin induced thrombocytopenia. Circulation, 2003, 108, 2062-65.
83. Cordenas, C.A., Deitcher, S.R. Risk of anaphylaxis after reexposure to intravenous Lepirudin in patients with current or past heparin induced thrombocytopenia. Mayo Clin. Proc., 2005, 80, 491-93.
84. Shammas, N.W. Bivaluridin: pharmacology and clinical applications Cardiovasc. Drug Rev., 2005, 23, 345-60.
85. Eichler, P., Lubenow, N., Strobel, U. Antobodies against Lepirudin and recognize epitopes on bivalirudin. Blood, 2004, 103, 613-16.
86. Hursting, M.J., Alford, K.L., Becker, J.C., Brooks, R.L., Joffrion, J.L., Knappenberger, G.D., Kogan, P.W., Kogan, T.P., McKinney, A.A., Scwarz, R.P. Jr. Novostan (brand of argatroban) a small molecule, direct thrombin inhibitor. Semin. Thromb. Hemost., 1997, 23, 503-16.
87. Fitzgrald, D., Murphy, N. Argatroban: a synthetic thrombin inhibitor of low relative molecular mass. Coronary Artery Dis., 1996, 7, 455-58.
88. Lewis, B.E., Wallis, D.E, Berkowitz, S.D., Matthai, W., Fareed, J., Walenga, J.M., Bartholomew, J., Sham, R., Lerner, R.G., Zeigler, Z.R., Rustagi, P.K., Jang, I.K., Rifkin, S.D., Moran, J., Bursting, M.J., Kelton, J.G. for the Arg-911 Study Investigators. Argatroban anticoagulant therapy in patients with heparin induced thrombocytopenia. Circulation, 2001, 14, 1838-43.
89. Boneu, B. Glycoaminoglycans: clinical use. Semin. Thromb. Hemost., 1996, 22, 209-12.
90. Magnani, H.N. Orgaran (Danaparoid sodium) use in the syndrome of heparin induced thrombocytopenia. Platelets, 1997, 8, 74-81.
91. Tardy-Poncet, B., Tardy, B., Reynaud, J., Mahul, P., Mismetti, P., Mazet, E., Guyotat, D. Efficacy and safety of danaparoid sodium (Org 10172) in critically ill patients with heparin induced thrombocytopenia. Chest, 1999, 115, 1616-20.
92. Tardy, B., Tardy-Poncet, B., Viallon, A., Piot, M., Mazet, E. Fatal daparanoid sodium induced thrombocytopenia and arterial thromboses. Thromb. Haemost., 1998, 80, 530.
93. Ontachi, Y., Asakura, H., Arahata, M., Kadoira, Y., Maekawa, M., Hayashi, T., Yamazaki, M., Morishita, E., Saito, M., Minami, S., Nakao, S. Effect of combined therapy of danaparoid sodium and tranexamic acid on chronic disseminated intravascular coagulation associated with abdominal aortic aneurysm. Circ. J., 2005, 69(9), 1150-3.
94. Ibbotson, T., Perry, C.M. Danaparoid: a review of its use in thromboembolic and coagulation disorders. Drugs, 2002, 62(15), 2283-2314.
95. Gouault-Heillmann, M., Huet, Y., Adnot, S., Contant, G., Bonnet, F., Intrator, L., Payent, D., Levent, M. Low molecular weight heparin fractions as an alternative therapy with low molecular weight heparin. Haemostasis, 1987, 17, 134-40.
96. Denton, J., Lane, D.A., Thunberg, L., Slater, A.M., Lindahl, U. Binding of platelet factor 4 to heparin oligosaccharides. Bioch. J., 1983, 209, 455-460.
97. Kikta, M.J., Keller, M.P., Humphrey, P.W., Silver, D. Can low molecular weight heparins and heparinoids be safely given to patients with heparin induced thrombocytopenia syndrome. Surgery, 1993, 114, 705-10.
98. Luzzato, G., Cordiano, I., Patrassi, G., Fabris, F. Heparin induced thrombocytopenia: discrepancy between the presence of IgG cross reacting in vitro with faxiparine and its success-full clinical use. Thromb. Haemost., 1995, 74, 1607-8.
99. Horellou, M.H., Conrad, J., Lecrubier, C., Samana, M., Roque-D'Orbcastel, O., de Fenoyl, O., Di Maria, G., Bernadou, A. Persistent heparin induced thrombocytopenia despite therapy with low molecular weight beparin. Thromb. Haemost., 1984, 51, 134.
100. Paolucci, F., Clavies, M., Donat, F. Fondaparinus sodium mechanism of action identification of specific binding to purified and human plasma derived proteins. Clin. Pharmacokinetics, 2002, 41(suppl.), 11-18.
101. Lormeau, J.C., Herald, J.P., Elalamy, L., Lecrubier, C., Potevin, F. Absence of in vitro cross reaction of penthasaccaride with the plasma beparin dependent factor of twenty five patients with associated heparin -induced thrombocytopenia. Thromb. Haemost., 1995, 74, 1384-1385.
102. Abroad, S., Jeske, W.P., Walenga, J.M. Synthetic penthasaccaride do not cause platelet activation by antiheparin-platelet factor 4 antibodies. Clin. App. Thromb. Hemost., 1999, 5, 259-26.
103. D' Angelo, A., Valle, P.D., Fattorini, A., Luciano, C. Disappearance of anti-PF4/heparin antibodies under prolonged fondaparinux administration in a patient with DVT associated with LMWH-induced thrombocytopenia. Thromb. Haemost., 2006, 95, 573-575.
104. Warkentin, T.E., Cook, R.J., Marder, V.J., Sheppard, J.A., Moore, J.C., Eriksson, B.I., Greinacher, A., Kelton, J.G. Anti-platelet factor 4/ heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinus or enoxaparin. Blood, 2005, 106, 3791-3796.
105. Walenga, J.M., Jeske, W. P., Wallis, D.E., Bakhos, M., Lewis, B.E., Leya, F., Fareed, J. Clinical experience with combined treatment of thrombin inhibitors and GPIIb/IIIa inhibitors in patients with HIT. Semin. Thromb. Hemost., 1999, 25(suppl. 1), 77-81.
106. Liem, T.K., Teel, R., Shula, S., Silver, D. The glycoprotein IIb/IIIa antagonist inhibit platelet aggregation in the presence of heparin associated antibodies. J. Vasc. Surg., 1997, 25, 124-130.
107. Megalopoulos, A., Vasiliadis, K., Tsachalis, T., Tsalis, K., Blouhos, K., Alexandridou, S., Betsis, D. Recurrent arterial thromboses in a woman with heparin induced thrombocytopenia, successfully managed with iloprost followed by clopidogrel. An alternative therapeutic option for heparin induced thrombocytopenia type II syndrome. Int. Angiology, 2006, 25, 84-87.
108. Fareed, J., Hoppensteadt, D.A., Jeske, P., Walenga, J.M., Ahmad, S., Torri, R. Immunosuppression results in a reduction in anti-heparin platelet factor 4 antibodies: implications in the management of heparin induced thrombocytopenia. Blood, 1999, 94(suppl. 1), 19a.
109. Mc Crae, K.R., Bussel, J.B., Mannucci, P.M., Remuzzi, G., Cines, D.B. Platelets: an update on diagnosis and managements of thrombocytopenic disorders. Hematology (Am. Soc. Hematol. Educ. Program), 2001, 282-305.
110. Lotke, P.A., Callaghan, J.J., Dorr, L.D., Engh, G.H., Hanssen, A.D., Healy, W.L., Lachiewicz, P.F., Lonner, J.H., Nelson, C., Ranawat, C.S., Ritter, M.A., Salvati, E.A., Sculco, T.P., Thornhill, T.S. Oral direct trombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty. J. Bone Joint Surg. Am., 2006, 88, 1163.
111. Garcia Vidal, R., Berga Fauria, C., Paredero, V.M. Deep vein thrombosis: new drug and future therapeutic perspectives. Rev. Clin. Esp., 2006, 206, 281-3.
112. Gomberg-Maitland, M., Wenger, N.K, Feyzi, J., Lengyel, M., Volgman, A.S., Petersen, P., Frison, L., Halperin, J.L. Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials. Eur. Heart J., 2006, (epub ahead of print).